Streetwise Cannabis Articles


When to Take Profits in the Cannabis Sector

Contributed Opinion
  ()
With a run-up in cannabis stocks, technical analyst Clive Maund shares his thoughts on when investors should take profits. read more >

2017: A Year of Triple Digit Stock Performance

  ()
As stock indexes in the U.S. hit record highs in 2017, we take a look at some of the best performers profiled by Streetwise Reports in the last year, some of which have seen triple digit increases. read more >

On the Brink of Legalization in California, Cannabis Company Stocks Should Soar

Contributed Opinion
  ()
Technical analyst Clive Maund provides an argument for why two cannabis companies are poised for big gains following the legalization of recreational marijuana in the state of California. read more >

Cannabis Biotech Stock Starting to Advance Again

Contributed Opinion
  ()
A technical analysis by Clive Maund on CliveMaund.com has a Buy on this cannabis biotech stock. read more >

AgriTech Company Sells to Organic and Cannabis Markets

  ()
The company's soon-to-be-announced prefeasibility study will evaluate expansion plans. read more >

The Lowdown on Getting High in Canada

Contributed Opinion
  ()
Some 600 tonnes of marijuana a year are up for grabs as Canada moves to legalize weed, says Rick Mills, founder of Ahead of the Herd, who puts forth his case on why cannabis stocks should be in every investor's portfolio. read more >

Cannabis Cultivator Poised to Profit When Recreational Marijuana Becomes Legal in Canada

Contributed Opinion
  ()
With the Canadian cannabis market primed to be worth billions upon legalization of recreational marijuana use, Lior Gantz of Wealth Research Group makes the case for an "undervalued" competitor. read more >

Cannabis Company Forms Partnership to Develop Pharmaceuticals

Research Report
  ()
Analyst Russell Stanley with Echelon Wealth Partners explained the significance of the recent licensing agreement signed by this Canadian medical marijuana producer and distributor. read more >

Gold Extremely Volatile: Stamina Check Underway

Contributed Opinion
  ()
Studying Warren Buffett's investment principles, says Lior Gantz, founder of Wealth Research Group, will help investors navigate today's volatile markets. read more >

Gout, Kidney Stones, Liver Disease & Cannabinoids

Contributed Opinion
  ()
Danny Deadlock, founder of Microcap.com, profiles a company that is working on a novel drug delivery technology with a focus on cannabinoids for the potential to treat various major diseases. read more >

Investors Should Be Paying Attention to Phosphate Right Now

Contributed Opinion
  ()
Nick Hodge of The Outsider Club sits down with Arianne Phosphate CEO Brian Ostroff to discuss recent developments at the company. read more >

Medical Cannabis Innovator Set to Go Public

Initial Public Offering
  ()
A licensed producer of medical cannabis in Canada will begin trading on the Canadian Securities Exchange on Aug. 21. read more >

Company Developing Cannabinoid-Based Drug Therapy for Concussions Completes Reverse Takeover

Reverse Takeover
  ()
A drug developer working on a treatment for concussions expects to begin trading on the TSX Venture Exchange on Aug. 8. read more >

This Just Changed Everything: Green Profits Are Being Unleashed

Contributed Opinion
  ()
Kenneth Ameduri, founder of Crush the Street, discusses why he believes now is a good time to take advantage of cannabis investing opportunities. read more >

Even George Soros Couldn't Resist This Speculation

Contributed Opinion
  ()
Tom Beck, founder of Portfolio Wealth Global, delves into the investment potential of cannabis in the U.S. read more >

Canadian Medical Cannabis Provider Expanding into US Market Through RTO

Reverse Takeover
  ()
A company with Canadian medical cannabis provider Aphria's backing is doing a reverse takeover on the Canadian Securities Exchange and expects to begin trading on July 26. read more >

The Marijuana Sector: Timing the Next Upleg

Contributed Opinion
  ()
Canadian and U.S. marijuana stocks have taken divergent paths over the last six months, and technical analyst Clive Maund examines why. read more >

Why the Canadian Marijuana Sector Is the Next Big Thing and Why Emblem Is Our Top Pick

Contributed Opinion
  ()
Gecko Research discusses the bull market for marijuana, the road to legalization in Canada and why Emblem Corp., which begins trading on the TSX.V on Dec. 12 under the symbol EMC, is their top pick. read more >

The Cannabis Sector after the Vote – Boom or Bust??

  ()
Technical Analyst Clive Maund takes a look at the cannabis sector, and how the the election results for eight states, including California, might facilitate a massive boom. read more >

Medical Marijuana Goes to Market: Daniel Pearlstein of M Partners

  ()
Life sciences analyst Daniel Pearlstein of Toronto-based M Partners offers his perspectives on six Canadian biotech and specialty pharma names with different value propositions and the capacity to grow multiples of invested capital, including one company in the budding medical marijuana field. read more >
Showing Results: 1 to 20 of 20

Get Our Streetwise Reports Newsletter Free

A valid email address is required to subscribe